Trades on 1 secondary market

Sanegenebio

SanegeneBio is a clinical-stage biotechnology company developing RNAi (RNA interference) genetic medicines for metabolic, cardiovascular, and complement-mediated autoimmune diseases, including obesity. Its proprietary LEAD (Ligand and Enhancer Assisted Delivery) platform enables receptor-mediated, t

minimal 11.9 / 100 0 APIs View provider profile →

Company Biotechnology Genetic Medicine RNAi Therapeutics Metabolic Disease

Sanegenebio is an API provider whose private shares are listed on 1 secondary market: EquityZen.

Where It Trades

EZ EquityZen View listing →

Listing data is compiled from the public marketplace pages of Forge Global, Hiive, EquityZen, Nasdaq Private Market, and Augment. A listing indicates that a venue has published a page for this company — it is not an offer, a quote, or investment advice, and APIs.io has no affiliation with any venue.